Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer?

Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer? Purpose To evaluate the diagnostic potential of DW-MRI relative parameters for differentiation of rectal cancers with different Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation status. Methods Fifty-one patients with rectal cancer underwent diffusion-weighted MR imaging with eight b values. ADCs (including Max-ADC, Min-ADC and Mean-ADC) and IVIM parameters (D, pure diffusion; f, perfusion fraction; D*, pseudodiffusion coefficient) were respectively calculated by mono- and bi-exponential analysis. Patients were stratified into two groups: KRAS wild type and mutant. The DW-MRI-derived parameters between the KRAS wild-type group and KRAS mutant group were compared using the Mann-Whitney U test. Receiver-operating characteristic (ROC) analysis of discrimination between KRAS wild-type and KRAS mutant rectal cancer was performed for the DW-MRI-derived parameters. Results Max-ADC, Mean-ADC and D values were significantly lower in the KRAS mutant group than in the KRAS wild-type group, whereas a higher D* value was demonstrated in the KRAS mutant group. According to the ROC curve, Mean-ADC and D* values showed moderate diagnostic significance with the AUC values of 0.756 and 0.710, respectively. The cut-off values for -3 2 -3 2 Mean-ADC and D* were 1.43 × 10 mm /s and 26.58 × 10 mm /s, respectively. Conclusion Rectal cancers had distinctive http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png European Radiology Springer Journals

Could IVIM and ADC help in predicting the KRAS status in patients with rectal cancer?

Download PDF
7 pages

Loading next page...
 
/lp/springer_journal/could-ivim-and-adc-help-in-predicting-the-kras-status-in-patients-with-22n1j3zMWu
Publisher
Springer Journals
Copyright
Copyright © 2018 by European Society of Radiology
Subject
Medicine & Public Health; Imaging / Radiology; Diagnostic Radiology; Interventional Radiology; Neuroradiology; Ultrasound; Internal Medicine
ISSN
0938-7994
eISSN
1432-1084
DOI
10.1007/s00330-018-5329-y
pmid
29450716
Publisher site
See Article on Publisher Site

Abstract

Purpose To evaluate the diagnostic potential of DW-MRI relative parameters for differentiation of rectal cancers with different Kirsten rat sarcoma viral oncogene homologue (KRAS) mutation status. Methods Fifty-one patients with rectal cancer underwent diffusion-weighted MR imaging with eight b values. ADCs (including Max-ADC, Min-ADC and Mean-ADC) and IVIM parameters (D, pure diffusion; f, perfusion fraction; D*, pseudodiffusion coefficient) were respectively calculated by mono- and bi-exponential analysis. Patients were stratified into two groups: KRAS wild type and mutant. The DW-MRI-derived parameters between the KRAS wild-type group and KRAS mutant group were compared using the Mann-Whitney U test. Receiver-operating characteristic (ROC) analysis of discrimination between KRAS wild-type and KRAS mutant rectal cancer was performed for the DW-MRI-derived parameters. Results Max-ADC, Mean-ADC and D values were significantly lower in the KRAS mutant group than in the KRAS wild-type group, whereas a higher D* value was demonstrated in the KRAS mutant group. According to the ROC curve, Mean-ADC and D* values showed moderate diagnostic significance with the AUC values of 0.756 and 0.710, respectively. The cut-off values for -3 2 -3 2 Mean-ADC and D* were 1.43 × 10 mm /s and 26.58 × 10 mm /s, respectively. Conclusion Rectal cancers had distinctive

Journal

European Radiology – Springer Journals

Published: Feb 15, 2018

References

  • Colorectal cancer
    Weizt, J; Koch, M; Debus, J; Höhler, T; Galle, PR; Büchler, MW
  • Genetics, cytogenetics, and epigenetics of colorectal cancer
    Migliore, L; Migheli, F; Spisni, R; Coppedè, F
  • KRAS mutant colorectal tumors: past and present
    Brand, TM; Wheeler, DL
  • KRAS mutation testing in human cancers: The pathologist's role in the era of personalized medicine
    Wang, HL; Lopategui, J; Amin, MB; Patterson, SD
  • Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer
    Bae, H; Yoshida, S; Matsuoka, Y
  • Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis
    Higano, S; Yun, X; Kumabe, T
  • Diffusion-weighted MRI in rectal cancer: apparent diffusion coefficient as a potential noninvasive marker of tumor aggressiveness
    Curvo-Semedo, L; Lambregts, DM; Maas, M; Beets, GL; Caseiro-Alves, F; Beets-Tan, RG
  • Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging
    Bihan, D; Breton, E; Lallemand, D; Aubin, ML; Vignaud, J; Laval-Jeantet, M
  • Rectal cancer: Short-term reproducibility of intravoxel incoherent motion parameters in 3.0T magnetic resonance imaging
    Sun, H; Xu, Y; Xu, Q
  • Intravoxel incoherent motion-derived histogram metrics for assessment of response after combined chemotherapy and radiation therapy in rectal cancer: initial experience and comparison between single-section and volumetric analyses
    Nougaret, S; Vargas, HA; Lakhman, Y
  • Intravoxel incoherent motion MRI for predicting early response to induction chemotherapy and chemoradiotherapy in patients with nasopharyngeal carcinoma
    Xiao-ping, Y; Jing, H; Fei-ping, L
  • Cellularity and apparent diffusion coefficient in oligodendroglial tumours characterized by genotype
    Jenkinson, MD; Plessis, DG; Smith, TS; Brodbelt, AR; Joyce, KA; Walker, C
  • Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study
    Guiu, B; Petit, JM; Capitan, V
  • Apparent Diffusion Coefficient (ADC) Value: a potential imaging biomarker that reflects the biological features of rectal cancer
    Sun, Y; Tong, T; Cai, S; Bi, R; Xin, C; Gu, Y
  • Nasopharyngeal carcinoma: comparison of diffusion and perfusion characteristics between different tumour stages using intravoxel incoherent motion MR imaging
    Lai, V; Li, X; Lee, VH
  • Predicting response to neoadjuvant chemoradiation therapy in locally advanced rectal cancer: diffusion-weighted 3 Tesla MR imaging
    Jung, SH; Heo, SH; Kim, JW
  • Activation of the K-ras oncogene in colorectal neoplasms is associated with decreased apoptosis
    Ward, RL; Todd, AV; Santiago, F; O'Connor, T; Hawkins, NJ
  • Effect of K-ras mutation on morphogenesis of colorectal adenomas and early cancers: relationship to distribution of proliferating cells
    Kobayashi, M; Watanabe, H; Ajioka, Y; Honma, T; Asakura, H
  • Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer
    Shigenori, K; Miho, K; Shuhei, T
  • Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
    Andreyev, HJ; Norman, AR; Cunningham, D
  • Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial
    Roth, AD; Tejpar, S; Delorenzi, M
  • Targeting RAS signaling pathways in the cancer therapy
    Downward, J
  • Specific TP53 and/ or K-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of 5-year Gruppo Oncologico dell’Italia Meridionale (GOIM) prospective study
    Bazan, V; Agnese, V; Corsale, S
  • Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
    Li, W; Qiu, T; Zhi, W
  • Genetic and epigenetic biomarkers for diagnosis, prognosis and treatment of colorectal cancer
    Coppedè, F; Lopomo, A; Spisni, R; Migliore, L
  • Predictive and prognostic roles of BRAF mutation in patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a meta-analysis
    Xu, Q; Xu, AT; Zhu, MM; Tong, JL; Xu, XT; Ran, ZH